EGCG (Epigallocatechin Gallate) Cancer Research Results

EGCG, EGCG (Epigallocatechin Gallate): Click to Expand ⟱
Features:
EGCG (Epigallocatechin Gallate) is found in green tea. 100 times more effective than Vitamin C and 25 times more effective than Vitamin E at protecting cells from damage associated with oxidative stress.
EGCG Epigallocatechin Gallate (Green Tea) -Catechin
Summary:
1. Concentration is a factor that could determine whether green tea polyphenols act as antioxidants or pro-oxidants.
2. Poor bioavailability: taking EGCG capsules without food was better.
3. Cancer dosage 4g/day (2g twice per day)? with curcumin may help (another ref says 700–2100 mg/d)
4. EGCG is susceptible to oxidative degradation.
5. “As for the pH level, the acidic environments enhance the stability of EGCG”.
6. “EGCG may enhance nanoparticle uptake by tumor cells”
7. Might be iron chelator (removing iron from cancer cells)
8. Claimed as synergistic effect with chemotherapy ( cisplatin, bleomycin, gemcitabine.
9. May suppress glucose metabolism, interfere with VEGF, downregulate NF-κB and MMP-9, down-regulation of androgen-regulated miRNA-21.
10. Take with red pepper powder, Capsicum ratio 25:1 (based on half life, they did every 4 hr) (chili pepper vanilloid capsaicin).
11. EGCG mediated ROS formation can upregulate CTR1 expression via the ERK1/2/NEAT1 pathway, which can increase the intake of chemotherapeutic drugs such as cisplatin in NSCLC cells and act as a chemosensitizer [58]
12. Matcha green tea has highest EGCG (2-3X) because consuming leaf.
13. EGCG is an ENOX2 inhibitor.
14. Nrf2 activator in both cancer and normal cells. This example of lung cancer show both directions in different cell lines, but both toward optimim level.
Biological activity, EGCG has been reported to exhibit a range of effects, including:
    Antioxidant activity: 10-50 μM
     Anti-inflammatory activity: 20-50 μM
     Anticancer activity: 50-100 μM
     Cardiovascular health: 20-50 μM
     Neuroprotective activity: 10-50 μM

Drinking a cup (or two cups) of green tea (in which one might ingest roughly 50–100 mg of EGCG from brewed tea) generally results in peak plasma EGCG concentrations in the range of approximately 0.1 to 0.6 μM.

With higher, supplement-type doses (e.g., oral doses in the 500 mg–800 mg range that are sometimes studied for clinical benefits), peak plasma concentrations in humans can reach the low micromolar range, often reported around ~1–2 μM and in some cases up to 5 μM.

Reported values can range from about 25–50 mg of EGCG per gram of matcha powder.
In cases where the matcha is exceptionally catechin-rich, the content could reach 200–250 mg or more in 5 g.

-Peak plasma concentration roughly 1 to 2 hours after oral ingestion.
-Elimination half-life of EGCG in plasma is commonly reported to be in the range of about 3 to 5 hours.

Supplemental EGCG
Dose (mg)   ≈ Peak Plasma EGCG (µM)
~50 mg          ≈ 0.1–0.3 µM
~100 mg         ≈ 0.2–0.6 µM
~250 mg         ≈ 0.5–1.0 µM
~500 mg         ≈ 1–2 µM
~800 mg or higher  ≈ 1–5 µM

50mg of EGCG in 1g of matcha tea(1/2 teaspoon)

Studies on green tea extracts have employed doses roughly equivalent to 300–800 mg/day of EGCG. Excessive doses can cause liver toxicity in some cases.

Methods to improve bioavailability
-Lipid-based carriers or nanoemulsions
-Polymer-based nanoparticles or encapsulation
-Co-administration with ascorbic acid (vitamin C)
-Co-administration of adjuvants like piperine (perhaps sunflower lecithin and chitosan) -Using multiple smaller doses rather than one large single dose.
-Taking EGCG on an empty stomach or under fasting conditions, or aligning dosing with optimal pH conditions in the GI tract, may improve its absorption.(acidic environment is generally more favorable for its stability and absorption).
– EGCG is more stable under acidic conditions. In the stomach, where the pH is typically around 1.5 to 3.5, EGCG is less prone to degradation compared to the more neutral or basic environments of the small intestine.
- At neutral (around pH 7) or alkaline pH, EGCG undergoes auto-oxidation, reducing the effective concentration available for absorption.
– Although the stomach’s acidic pH helps maintain EGCG’s stability, most absorption occurs in the small intestine, where the pH is closer to neutral.
– To counterbalance the inherent instability in the intestine, strategies such as co-administration of pH-modifying agents (like vitamin C) are sometimes used. These agents help to maintain a slightly acidic environment in the gut microenvironment, potentially improving EGCG stability during its transit and absorption.
– The use of acidifiers or buffering agents in supplements may help preserve EGCG until it reaches the absorption sites.

-Note half-life 3–5 hours.
- low BioAv 1%? despite its limited absorption, it is rapidly disseminated throughout the body
Pathways:
- induce ROS production
- ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, GRP78↑, Ca+2↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, HSP↓, Prx,
- Does NOT Lower AntiOxidant defense in Cancer Cells: NRF2↑, TrxR↓**, SOD, GSH Catalase HO1 GPx
- Raises AntiOxidant defense in Normal Cells: ROS↓, NRF2↑, SOD↑, GSH↑, Catalase↑,
- lowers Inflammation : NF-kB↓, COX2↓, p38↓, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓
- inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMPs↓, MMP2↓, MMP9↓, IGF-1↓, uPA↓, VEGF↓, FAK↓, RhoA↓, NF-κB↓, TGF-β↓, α-SMA↓, ERK↓
- reactivate genes thereby inhibiting cancer cell growth : HDAC↓, DNMTs↓, EZH2↓, P53↑, HSP↓, Sp proteins↓,
- cause Cell cycle arrest : TumCCA↑, cyclin D1↓, cyclin E↓, CDK2↓, CDK4↓, CDK6↓,
- inhibits Migration/Invasion : TumCMig↓, TumCI↓, TNF-α↓, FAK↓, ERK↓, EMT↓, TOP1↓,
- inhibits glycolysis /Warburg Effect and ATP depletion : HIF-1α↓, PKM2↓, cMyc↓, GLUT1↓, LDH↓, LDHA↓, HK2↓, PFKs↓, ECAR↓, OXPHOS↓, GRP78↑, Glucose↓, GlucoseCon↓
- inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, Notch↓, FGF↓, PDGF↓, EGFR↓, Integrins↓,
- inhibits Cancer Stem Cells : CSC↓, Hh↓, GLi↓, GLi1↓, CD133↓, CD24↓, β-catenin↓, n-myc↓, Notch↓, OCT4↓,
- Others: PI3K↓, AKT↓, JAK↓, STAT↓, Wnt↓, β-catenin↓, AMPK, ERK↓, JNK, - SREBP (related to cholesterol).
- Synergies: chemo-sensitization, chemoProtective, RadioSensitizer, RadioProtective, Others(review target notes), Neuroprotective, Cognitive, Renoprotection, Hepatoprotective(possible damage at high dose), CardioProtective,

- Selectivity: Cancer Cells vs Normal Cells

Rank Pathway / Axis Cancer Cells Normal Cells Label Primary Interpretation Notes
1 Reactive oxygen species (ROS) ↑ ROS (dose-, metal-, context-dependent) ↓ ROS / buffered Conditional Driver Biphasic redox modulation EGCG can act as a pro-oxidant in cancer cells (often metal-catalyzed) while functioning as an antioxidant in normal cells
2 Mitochondrial integrity / intrinsic apoptosis ↓ ΔΨm; ↑ caspase activation ↔ preserved Driver Execution of intrinsic apoptosis Mitochondrial stress and apoptosis follow ROS elevation in cancer cells
3 NF-κB signaling ↓ NF-κB activation ↓ inflammatory NF-κB tone Driver Suppression of survival and inflammatory transcription NF-κB inhibition explains chemosensitization and reduced survival signaling
4 PI3K → AKT → mTOR axis ↓ AKT / ↓ mTOR ↔ adaptive suppression Secondary Reduced growth and anabolic signaling AKT/mTOR inhibition contributes to growth suppression and stress responses
5 MAPK stress signaling (JNK / p38) ↑ JNK / ↑ p38 ↔ minimal Secondary Stress-activated apoptosis signaling MAPK activation often follows ROS increase and supports apoptotic signaling
6 Cell cycle regulation ↑ G1 or G2/M arrest ↔ largely spared Phenotypic Cytostatic growth control Cell-cycle arrest reflects upstream signaling disruption rather than direct CDK inhibition
7 HIF-1α / VEGF hypoxia–angiogenesis axis ↓ HIF-1α; ↓ VEGF ↔ minimal Secondary Anti-angiogenic pressure EGCG interferes with hypoxia-driven tumor adaptation
8 NRF2 antioxidant response ↑ NRF2 (adaptive, often insufficient) ↑ NRF2 (protective) Adaptive Stress compensation NRF2 reflects response to redox perturbation rather than a kill mechanism


Scientific Papers found: Click to Expand⟱
1541- Api,  EGCG,    Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence
- Human, NA, NA
OS↑, Remission↓, Dose∅,
147- ATG,  EGCG,  CUR,    Increased chemopreventive effect by combining arctigenin, green tea polyphenol and curcumin in prostate and breast cancer cells
- in-vitro, Pca, LNCaP - in-vitro, Pca, MCF-7
Bax:Bcl2↑, NF-kB↓, PI3K/Akt↓, STAT3↓, chemoPv↑, TumCP↓, TumCCA↑, TumCMig↓,
3754- BBR,  CUR,  EGCG,  Hup,    Traditional Chinese medicinal herbs as potential AChE inhibitors for anti-Alzheimer’s disease: A review
*AChE↓, *Aβ↓, *LDL↓, *RenoP↑, *BChE↓, *eff↑, *BACE↓, *AChE↓, *eff↑,
5397- CUR,  SFN,  RES,  EGCG,  Ash  Targeting Cancer Stem Cells with Phytochemicals: Molecular Mechanisms and Therapeutic Potential
- Review, Var, NA
CSCs↓,
4881- CUR,  SFN,  RES,  EGCG,  Lyco  An update of Nrf2 activators and inhibitors in cancer prevention/promotion
- Review, Var, NA
*NRF2↑, *antiOx↑,
4656- CUR,  EGCG,    Curcumin and epigallocatechin gallate inhibit the cancer stem cell phenotype via down-regulation of STAT3-NFκB signaling
- in-vitro, BC, MDA-MB-231 - in-vitro, BC, MCF-7
CSCs↓, CD44↓, p‑STAT3↓, NF-kB↓, TumCI↓,
146- CUR,  EGCG,    Synergistic effect of curcumin on epigallocatechin gallate-induced anticancer action in PC3 prostate cancer cells
- in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP - in-vitro, Pca, DU145
P21↑, TumCCA↑, TumCP↓, BioAv↓,
162- CUR,  EGCG,  SFN,    Shattering the underpinnings of neoplastic architecture in LNCap: synergistic potential of nutraceuticals in dampening PDGFR/EGFR signaling and cellular proliferation
- in-vitro, Pca, LNCaP
p‑PDGF↓,
2501- EGCG,    A Case of Complete and Durable Molecular Remission of Chronic Lymphocytic Leukemia Following Treatment with Epigallocatechin-3-gallate, an Extract of Green Tea
- Case Report, AML, NA
OS↑, Remission↑, eff↑, Dose↝,
2459- EGCG,    Epigallocatechin gallate inhibits human tongue carcinoma cells via HK2‑mediated glycolysis
- in-vitro, Tong, Tca8113 - in-vitro, Tong, TSCCa
EGFR↓, Akt↓, ERK↓, HK2↓, GlucoseCon↓, lactateProd↓, Glycolysis↓,
2561- EGCG,  ASA,    Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment
- ex-vivo, Nor, NA
AntiAg↑, eff↑, Half-Life↝, other∅,
2562- EGCG,    Green Tea Epigallocatechin 3-Gallate Reduced Platelet Aggregation and Improved Anticoagulant Proteins in Patients with Transfusion-Dependent β-Thalassemia: A Randomized Placebo-Controlled Clinical Trial
- Trial, NA, NA
AntiAg↑, other↝,
2563- EGCG,    Cardioprotective effect of epigallocatechin gallate in myocardial ischemia/reperfusion injury and myocardial infarction: a meta-analysis in preclinical animal studies
- Review, NA, NA
cardioP↑, ROS↑, AntiAg↑, eff↑, COX1↓,
2992- EGCG,    Effects of Epigallocatechin-3-Gallate on Matrix Metalloproteinases in Terms of Its Anticancer Activity
- Review, Var, NA
AP-1↓, Sp1/3/4↓, NF-kB↓, ERK↓, P-gp↓, HSP27↓, β-catenin/ZEB1↓, MMPs↓, TNF-α↓, IL1β↓, MMP2↓,
2993- EGCG,    Tea polyphenols down-regulate the expression of the androgen receptor in LNCaP prostate cancer cells
- in-vitro, Pca, LNCaP
TumCG↓, PSA↓, HK2↓, AR↓, Sp1/3/4↓,
2994- EGCG,    Nano-Engineered Epigallocatechin Gallate (EGCG) Delivery Systems: Overcoming Bioavailability Barriers to Unlock Clinical Potential in Cancer Therapy
- Review, Var, NA
BioAv↓, NF-kB↓, Casp↑, MMP9↑, Sp1/3/4↑,
3201- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*AntiCan↑, *cardioP↑, *neuroP↑, *BioAv↝, *BioAv↓, *BioAv↓, *Dose↝, *Half-Life↝, *BioAv↑, *BBB↑, *hepatoP↓, *other↓, *Inflam↓, *NF-kB↓, *AP-1↓, *iNOS↓, *COX2↓, *ROS↓, *RNS↓, *IL8↓, *JAK↓, *PDGFR-BB↓, *IGF-1R↓, *MMP2↓, *P53↓, *NRF2↑, *TNF-α↓, *IL6↓, *E2Fs↑, *SOD1↑, *SOD2↑, Casp3↑, Cyt‑c↑, PARP↑, DNMTs↓, Telomerase↓, Hif1a↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, TumCP↓, MAPK↓, HGF/c-Met↓, TIMP1↑, HDAC↓, MMP9↓, uPA↓, GlutMet↓, ChemoSen↑, chemoP↑,
3202- EGCG,    Epigallocatechin-3-gallate enhances ER stress-induced cancer cell apoptosis by directly targeting PARP16 activity
- in-vitro, Cerv, HeLa - in-vitro, HCC, QGY-7703
PARP16↓, p‑PERK↓, Apoptosis↑, eIF2α↓, UPR↓, ER Stress↑, eff↑, GRP78/BiP↓,
3203- EGCG,    (-)- Epigallocatechin-3-gallate induces GRP78 accumulation in the ER and shifts mesothelioma constitutive UPR into proapoptotic ER stress
- NA, MM, NA
ROS↑, Ca+2↝, GRP78/BiP↑, ATF4↑, XBP-1↑, CHOP↑, Casp3↑, Casp8↑, *GRP78/BiP↓, *UPR↓, UPR↑,
3204- EGCG,    The Role of ER Stress and the Unfolded Protein Response in Cancer
- Review, Var, NA
BID↓, UPR↑, ER Stress↑,
3205- EGCG,    The Role of Epigallocatechin-3-Gallate in Autophagy and Endoplasmic Reticulum Stress (ERS)-Induced Apoptosis of Human Diseas
- Review, Var, NA - Review, AD, NA
Beclin-1↑, ROS↑, Apoptosis↑, ER Stress↑, *Inflam↓, *cardioP↑, *antiOx↑, *LDL↓, *NF-kB↓, *MPO↓, *glucose↓, *ROS↓, ATG5↑, LC3B↑, MMP↑, lactateProd↓, VEGF↓, Zeb1↑, Wnt↑, IGF-1R↑, Fas↑, Bak↑, BAD↑, TP53↓, Myc↓, Casp8↓, LC3II↑, NOTCH3↓, eff↑, p‑Akt↓, PARP↑, *Cyt‑c↓, *BAX↓, *memory↑, *neuroP↑, *Ca+2?, GRP78/BiP↑, CHOP↑, ATF4↑, Casp3↑, Casp8↑, UPR↑,
3206- EGCG,    Insights on the involvement of (-)-epigallocatechin gallate in ER stress-mediated apoptosis in age-related macular degeneration
- Review, AMD, NA
*Ca+2↓, *ROS↓, *Apoptosis↓, *GRP78/BiP↓, *CHOP↓, *PERK↓, *IRE1↓, *p‑PARP↓, *Casp3↓, *Casp12↓, *ER Stress↓, *UPR↓,
3207- EGCG,    EGCG Enhances the Chemosensitivity of Colorectal Cancer to Irinotecan through GRP78-MediatedEndoplasmic Reticulum Stress
- in-vitro, CRC, RKO - in-vitro, CRC, HCT116
GRP78/BiP↑, MMP↓, ER Stress↑, ROS↓, UPR↑,
3208- EGCG,    Induction of Endoplasmic Reticulum Stress Pathway by Green Tea Epigallocatechin-3-Gallate (EGCG) in Colorectal Cancer Cells: Activation of PERK/p-eIF2α/ATF4 and IRE1α
- in-vitro, Colon, HT29 - in-vitro, Nor, 3T3
TumCD↓, ER Stress↑, GRP78/BiP↑, PERK↑, eIF2α↑, ATF4↑, IRE1↑, Apoptosis↑, Casp3↑, Casp7↑, Wnt↓, β-catenin/ZEB1↓, *toxicity∅, UPR↑,
3209- EGCG,    Epigallocatechin gallate upregulates NRF2 to prevent diabetic nephropathy via disabling KEAP1
- in-vitro, Diabetic, NA
*NRF2↑,
3210- EGCG,    Protective effect of epigallocatechin-3-gallate (EGCG) via Nrf2 pathway against oxalate-induced epithelial mesenchymal transition (EMT) of renal tubular cells
- in-vitro, Nor, NA
*ROS↓, *NRF2↑, *Catalase↑, *antiOx↑,
3211- EGCG,    Antioxidation Function of EGCG by Activating Nrf2/HO-1 Pathway in Mice with Coronary Heart Disease
- in-vivo, NA, NA
*cardioP↑, *VEGF↓, *MMP2↓, *SOD↑, *ROS↓, *HO-1↑, *NQO1↑, *NRF2↑,
1975- EGCG,    Molecular bases of thioredoxin and thioredoxin reductase-mediated prooxidant actions of (-)-epigallocatechin-3-gallate
- in-vitro, Cerv, HeLa
TrxR↓, Trx↓, ROS↑, Dose↑,
1071- EGCG,    Green tea polyphenols modulate insulin secretion by inhibiting glutamate dehydrogenase
- in-vitro, Nor, NA
*GDH↓,
1072- EGCG,    Epigallocatechin gallate (EGCG) suppresses epithelial-Mesenchymal transition (EMT) and invasion in anaplastic thyroid carcinoma cells through blocking of TGF-β1/Smad signaling pathways
- in-vitro, Thyroid, 8505C
EMT↓, TumCI↓, TumCMig↓, TGF-β↓, p‑SMAD2↓, p‑SMAD3↓, SMAD4↓,
1303- EGCG,    (-)-Epigallocatechin-3-gallate induces apoptosis in human endometrial adenocarcinoma cells via ROS generation and p38 MAP kinase activation
- in-vitro, EC, NA
TumCP↓, ER-α36↓, cycD1/CCND1↓, ERK↑, Jun↓, BAX↑, Bcl-2↓, cl‑Casp3↑, ROS↑, p38↑,
1503- EGCG,    Epigenetic targets of bioactive dietary components for cancer prevention and therapy
- Review, NA, NA
selectivity↑, DNMT1↓, RECK↑, MMPs↓, TumCI↓, angioG↓, TumMeta↓, HATs↓, IκB↑, NF-kB↓, IL6↓, COX2↓, NOS2↓, ac‑H3↑, ac‑H4↑, eff↑,
1514- EGCG,    Preferential inhibition by (-)-epigallocatechin-3-gallate of the cell surface NADH oxidase and growth of transformed cells in culture
- in-vitro, Cerv, HeLa - in-vitro, Nor, MCF10
selectivity↑, *toxicity∅, TumCG↓, NADHdeh?, eff↑, ENOX2↓, Dose?,
1515- EGCG,  Phen,    Reciprocal Relationship Between Cytosolic NADH and ENOX2 Inhibition Triggers Sphingolipid-Induced Apoptosis in HeLa Cells
- in-vitro, Cerv, HeLa - in-vitro, Nor, MCF10 - in-vitro, BC, BT20
selectivity↑, ENOX2↓, NADH↑, SK↓, eff↑, aSmase↑,
1516- EGCG,    Epigallocatechin Gallate (EGCG): Pharmacological Properties, Biological Activities and Therapeutic Potential
- Review, NA, NA
*Dose∅, Half-Life∅, BioAv∅, BBB↑, toxicity∅, eff↓, Apoptosis↑, Casp3↑, Cyt‑c↑, cl‑PARP↑, DNMTs↓, Telomerase↓, angioG↓, Hif1a↓, NF-kB↓, MMPs↓, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, P53↑, PTEN↑, IGF-1↓, H3↓, HDAC1↓, *LDH↓, *ROS↓,
1974- EGCG,    Protective Effect of Epigallocatechin-3-Gallate in Hydrogen Peroxide-Induced Oxidative Damage in Chicken Lymphocytes
- in-vitro, Nor, NA
*ROS↓, *NO↓, *MMP↑, *i-Ca+2↓, *HO-1↑, *Catalase↑, *NRF2↑, *Trx1↑, *antiOx↑, *SOD↑, *Apoptosis↓,
2468- EGCG,    Green tea epigallocatechin-3-gallate inhibits platelet signalling pathways triggered by both proteolytic and non-proteolytic agonists
- in-vitro, Nor, NA
*AntiAg↑, *Ca+2↓,
1976- EGCG,    Epigallocatechin-3-gallate exhibits anti-tumor effect by perturbing redox homeostasis, modulating the release of pro-inflammatory mediators and decreasing the invasiveness of glioblastoma cells
- in-vitro, GBM, U87MG
ROS↑, MMP↓, Casp3↑, Cyt‑c↑, Trx1↓, Ceru↓, IL6↓, IL8↓, MCP1↓, RANTES?, uPA↝, ROS↑,
2302- EGCG,    Flavonoids Targeting HIF-1: Implications on Cancer Metabolism
- Review, Var, NA
TumCP↓, Hif1a↓, LDHA↓, PFK↓, cardioP↑, Glycolysis↓, PKM2↓,
2309- EGCG,  Chemo,    Targeting Glycolysis with Epigallocatechin-3-Gallate Enhances the Efficacy of Chemotherapeutics in Pancreatic Cancer Cells and Xenografts
- in-vitro, PC, MIA PaCa-2 - in-vitro, Nor, HPNE - in-vitro, PC, PANC1 - in-vivo, NA, NA
TumCG↓, eff↑, ROS↑, ECAR↓, ChemoSen↑, selectivity↑, Glycolysis↓, PFK↓, PKA↓, HK2∅, LDHA∅, PFKP↓, PKM2↓, H2O2↑, TumW↓,
2310- EGCG,    Epigallocatechin-3-gallate downregulates PDHA1 interfering the metabolic pathways in human herpesvirus 8 harboring primary effusion lymphoma cells
- in-vitro, lymphoma, PEL
GLUT3↑, PDHA1↓, GDH↓, ROS↑, Glycolysis↓, OXPHOS↓,
2395- EGCG,    EGCG inhibits diabetic nephrophathy through up regulation of PKM2
- Study, Diabetic, NA
*PKM2↑, *Apoptosis↓, *PGC-1α↑,
2458- EGCG,  QC,    Identification of plant-based hexokinase 2 inhibitors: combined molecular docking and dynamics simulation studies
- Analysis, Nor, NA
HK2↓,
3213- EGCG,  Rad,    Epigallocatechin-3-gallate Enhances Radiation Sensitivity in Colorectal Cancer Cells Through Nrf2 Activation and Autophagy
- in-vitro, CRC, HCT116
RadioS↑, TumCP↓, NRF2↑,
2460- EGCG,  Taur,    Anti-fibrosis activity of combination therapy with epigallocatechin gallate, taurine and genistein by regulating glycolysis, gluconeogenesis, and ribosomal and lysosomal signaling pathways in HSC-T6 cells
- in-vitro, Nor, HSC-T6
HK2↓,
3240- EGCG,    Green tea constituents (−)-epigallocatechin-3-gallate (EGCG) and gallic acid induce topoisomerase I– and topoisomerase II–DNA complexes in cells mediated by pyrogallol-induced hydrogen peroxide
- in-vitro, AML, K562
TOP1↑, TOP2↑,
3231- EGCG,    Epigallocatechin-3-gallate restores mitochondrial homeostasis impairment by inhibiting HDAC1-mediated NRF1 histone deacetylation in cardiac hypertrophy
- in-vitro, Nor, NA
*HDAC↓, *cardioP↑, *Nrf1↑, *PGC-1α↓,
3232- EGCG,    (−)-Epigallocatechin-3-gallate attenuates cognitive deterioration in Alzheimer׳s disease model mice by upregulating neprilysin expression
- in-vivo, AD, NA
HDAC1↓, *HDAC1↓, *Aβ↓, *cognitive↑,
3233- EGCG,    Epigallocatechin gallate inhibits HeLa cells by modulation of epigenetics and signaling pathways
- in-vitro, Cerv, HeLa
DNMTs↓, DNMT1↓, DNMT3A↓, HDAC2↓, HDAC3↓, HDAC4↓, EZH2↓, PI3K↓, Wnt↓, MAPK↓, hTERT/TERT↓, MMP2↓, MMP7↓, IL6↓, MDM2↓, MMP-10↓, TP53↑, PTEN↑,
3234- EGCG,  Rad,    EGCG, a tea polyphenol, as a potential mitigator of hematopoietic radiation injury in mice
- in-vivo, Nor, NA
*DNMTs↓, *radioP↑, *HDAC↑,

Showing Research Papers: 1 to 50 of 174
Page 1 of 4 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 174

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Ceru↓, 1,   ENOX2↓, 2,   H2O2↑, 1,   NADH↑, 1,   NADHdeh?, 1,   NRF2↑, 1,   OXPHOS↓, 1,   ROS↓, 1,   ROS↑, 9,   Trx↓, 1,   Trx1↓, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↓, 2,   MMP↑, 1,  

Core Metabolism/Glycolysis ⓘ

ECAR↓, 1,   GDH↓, 1,   GlucoseCon↓, 1,   GlutMet↓, 1,   Glycolysis↓, 4,   HK2↓, 4,   HK2∅, 1,   lactateProd↓, 2,   LDHA↓, 1,   LDHA∅, 1,   PDHA1↓, 1,   PFK↓, 2,   PFKP↓, 1,   PI3K/Akt↓, 1,   PKM2↓, 2,  

Cell Death ⓘ

Akt↓, 1,   p‑Akt↓, 1,   Apoptosis↑, 4,   aSmase↑, 1,   BAD↑, 1,   Bak↑, 3,   BAX↑, 3,   Bax:Bcl2↑, 1,   Bcl-2↓, 3,   Bcl-xL↓, 2,   BID↓, 1,   Casp↑, 1,   Casp3↑, 6,   cl‑Casp3↑, 1,   Casp7↑, 1,   Casp8↓, 1,   Casp8↑, 2,   Cyt‑c↑, 3,   Fas↑, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 1,   MAPK↓, 2,   MDM2↓, 1,   Myc↓, 1,   p38↑, 1,   SK↓, 1,   Telomerase↓, 2,   TumCD↓, 1,  

Kinase & Signal Transduction ⓘ

Sp1/3/4↓, 2,   Sp1/3/4↑, 1,  

Transcription & Epigenetics ⓘ

EZH2↓, 1,   H3↓, 1,   ac‑H3↑, 1,   ac‑H4↑, 1,   HATs↓, 1,   other↝, 1,   other∅, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 2,   eIF2α↓, 1,   eIF2α↑, 1,   ER Stress↑, 5,   GRP78/BiP↓, 1,   GRP78/BiP↑, 4,   HSP27↓, 1,   IRE1↑, 1,   PERK↑, 1,   p‑PERK↓, 1,   UPR↓, 1,   UPR↑, 5,   XBP-1↑, 1,  

Autophagy & Lysosomes ⓘ

ATG5↑, 1,   Beclin-1↑, 1,   LC3B↑, 1,   LC3II↑, 1,  

DNA Damage & Repair ⓘ

DNMT1↓, 2,   DNMT3A↓, 1,   DNMTs↓, 3,   P53↑, 2,   PARP↑, 2,   cl‑PARP↑, 1,   TP53↓, 1,   TP53↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   P21↑, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

CD44↓, 1,   CSCs↓, 2,   EMT↓, 1,   ERK↓, 2,   ERK↑, 1,   HDAC↓, 1,   HDAC1↓, 2,   HDAC2↓, 1,   HDAC3↓, 1,   HDAC4↓, 1,   IGF-1↓, 1,   IGF-1R↑, 1,   Jun↓, 1,   NOTCH3↓, 1,   PI3K↓, 1,   PTEN↑, 3,   STAT3↓, 1,   p‑STAT3↓, 1,   TOP1↑, 1,   TOP2↑, 1,   TumCG↓, 3,   Wnt↓, 2,   Wnt↑, 1,  

Migration ⓘ

AntiAg↑, 3,   AP-1↓, 1,   Ca+2↝, 1,   ER-α36↓, 1,   MMP-10↓, 1,   MMP2↓, 2,   MMP7↓, 1,   MMP9↓, 1,   MMP9↑, 1,   MMPs↓, 4,   p‑PDGF↓, 1,   PKA↓, 1,   RECK↑, 1,   p‑SMAD2↓, 1,   p‑SMAD3↓, 1,   SMAD4↓, 1,   TGF-β↓, 1,   TIMP1↑, 1,   TumCI↓, 3,   TumCMig↓, 2,   TumCP↓, 6,   TumMeta↓, 1,   uPA↓, 1,   uPA↝, 1,   Zeb1↑, 1,   β-catenin/ZEB1↓, 2,  

Angiogenesis & Vasculature ⓘ

angioG↓, 2,   ATF4↑, 3,   EGFR↓, 1,   Hif1a↓, 3,   VEGF↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   GLUT3↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX1↓, 1,   COX2↓, 1,   IL1β↓, 1,   IL6↓, 3,   IL8↓, 1,   IκB↑, 1,   MCP1↓, 1,   NF-kB↓, 6,   PSA↓, 1,   RANTES?, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv∅, 1,   ChemoSen↑, 2,   Dose?, 1,   Dose↑, 1,   Dose↝, 1,   Dose∅, 1,   eff↓, 1,   eff↑, 9,   Half-Life↝, 1,   Half-Life∅, 1,   RadioS↑, 1,   selectivity↑, 4,  

Clinical Biomarkers ⓘ

AR↓, 1,   EGFR↓, 1,   EZH2↓, 1,   hTERT/TERT↓, 1,   IL6↓, 3,   Myc↓, 1,   NOS2↓, 1,   PSA↓, 1,   TP53↓, 1,   TP53↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 2,   chemoP↑, 1,   chemoPv↑, 1,   OS↑, 2,   PARP16↓, 1,   Remission↓, 1,   Remission↑, 1,   toxicity∅, 1,   TumW↓, 1,  
Total Targets: 195

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 4,   Catalase↑, 2,   HO-1↑, 2,   MPO↓, 1,   NQO1↑, 1,   Nrf1↑, 1,   NRF2↑, 6,   RNS↓, 1,   ROS↓, 7,   SOD↑, 2,   SOD1↑, 1,   SOD2↑, 1,   Trx1↑, 1,  

Mitochondria & Bioenergetics ⓘ

MMP↑, 1,   PGC-1α↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis ⓘ

GDH↓, 1,   glucose↓, 1,   LDH↓, 1,   LDL↓, 2,   PKM2↑, 1,  

Cell Death ⓘ

Apoptosis↓, 3,   BAX↓, 1,   Casp12↓, 1,   Casp3↓, 1,   Cyt‑c↓, 1,   iNOS↓, 1,  

Transcription & Epigenetics ⓘ

other↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 2,   IRE1↓, 1,   PERK↓, 1,   UPR↓, 2,  

DNA Damage & Repair ⓘ

DNMTs↓, 1,   P53↓, 1,   p‑PARP↓, 1,  

Cell Cycle & Senescence ⓘ

E2Fs↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1,   HDAC↑, 1,   HDAC1↓, 1,   IGF-1R↓, 1,  

Migration ⓘ

AntiAg↑, 1,   AP-1↓, 1,   Ca+2?, 1,   Ca+2↓, 2,   i-Ca+2↓, 1,   MMP2↓, 2,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,   PDGFR-BB↓, 1,   VEGF↓, 1,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   IL6↓, 1,   IL8↓, 1,   Inflam↓, 2,   JAK↓, 1,   NF-kB↓, 2,   TNF-α↓, 1,  

Synaptic & Neurotransmission ⓘ

AChE↓, 2,   BChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 2,   BACE↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 2,   BioAv↑, 1,   BioAv↝, 1,   Dose↝, 1,   Dose∅, 1,   eff↑, 2,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

IL6↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 4,   cognitive↑, 1,   hepatoP↓, 1,   memory↑, 1,   neuroP↑, 2,   radioP↑, 1,   RenoP↑, 1,   toxicity∅, 2,  
Total Targets: 81

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:73  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page